AASCIT - Journal - All Issues

ISSN: 2375-3838

International Journal of Clinical Medicine Research

The Journal

Manuscript Information

Cystatin C: An Important Biomarker for Evaluating Early Renal Dysfunction in the Hypertensive Patients of Kolkata, West Bengal

International Journal of Clinical Medicine Research
Vol.5 , No. 3, Publication Date: May 16, 2018, Page: 50-54

515 Views Since May 16, 2018, 367 Downloads Since May 16, 2018

Paper in PDF (1310K)

Follow on

Authors

[1]	Rinini Dastidar, Department of Biochemistry, Ramakrishna Mission Seva Pratishthan Vivekananda Institute of Medical Sciences, Kolkata, India.
[2]	Tanmoy Chattophadhyay, Department of Medicine, Ramakrishna Mission Seva Pratishthan Vivekananda Institute of Medical Sciences, Kolkata, India.
[3]	Tirna Halder, Department of Biochemistry, Ramakrishna Mission Seva Pratishthan Vivekananda Institute of Medical Sciences, Kolkata, India.

Abstract

Background: Hypertension has been recognized as one of the causes of Chronic Kidney Disease as it contributes to 40% of all CKD cases. Cr and eGFR calculated from creatinine based equation has been in practice for diagnosis and treatment of CKD for ages. Cystatin C, a polypeptide synthesized by all nucleated cells has been found to play a major role in detection of early renal impairment in hypertensive nephropathy patients. Objective: To compare the role of serum creatinine and cystatin C in diagnosing early CKD. Method: A total of 88 hypertensive patients and 70 controls were enrolled in the study. HTN patients were grouped as Stage I and Stage II on the basis of their blood pressure. eGFR was calculated by different equations based on estimated serum creatinine and cystatin C. Results: The serum creatinine, cystatin C and blood pressure of the subjects were observed to be much higher in both stage I and stage II hypertensives as compared to their controls (cr: 1.29±0.56 &1.54±0.91 vs 0.72±0.13; cysC: 1.42±0.82 &1.98±1.02 vs 0.76±0.21; SBP: 142.33±13.2 & 167.57±8.5 vs 128.89±14.1). Cystatin C showed more positive correlation with SBP (r= 0.323; p=0.0092) than creatinine (r=0.1068; p=0.3617 [NS]). An inverse association of eGFR with both creatinine and cysC was found in the hypertensive in comparison to their peer normotensives (58±17.6 & 54.48±25.32 vs 107.41±19.14). But cysC based eGFR was much reduced than creatinine based one thus indicating its importance in early detection of CKD. Conclusion: Serum cystatin C was proved to be a better predictor of CKD than creatinine among hypertensive patients.

Keywords

Cystatin C, Hypertension, Renal Marker, Creatinine, eGFR

Reference

[01]	Arindam Sur. Cystatin C, A Better Predictor of Renal Impairment in Essential Hypertensive Patients. International Journal of Clinical Biochemistry and Research 2015; 2 (3): 123-129.
[02]	Sur A, Mishra PK, Swain M, Mohapatra N. Study of Relationship between Kidney Function and Systolic Blood Pressure: New Insights from Cystatin C. Biochem Anal Biochem 2015; 4 (4): 226-230.
[03]	Shlipak MG, Katz R, Sarnak MJ, Fried LF, Newman AB, et al. Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease Ann Intern Med. 2006; 145 (4): 237-246.
[04]	Delanaye P, Cavalier E, Krzesinski JM. Cystatin C, renal function, and cardiovascular risk. Ann Intern Med 2008; 148: 323.
[05]	Franceschini N, Qiu C, Barrow DA, Williams MA. Cystatin C and preeclampsia: a case control study. Ren Fail 2008; 30: 89-95.
[06]	Bloomfield GS, Yi SS, Astor B C, Kramer H, Shea S, Shlipak MG and Post WS. Blood pressure and chronic kidney disease progression in a multi-racial cohort: the Multi-Ethnic Study of Atherosclerosis. Journal of Human Hypertension 2013; 27: 421-426.
[07]	Salgadoa JV, Françab AK, Cabralb NA, Lagesa J, Ribeiroc VS, Santosc AM. Cystatin C, kidney function, and cardiovascular risk factors in primary hypertension. Rev Assoc Med Bras. 2013; 59 (1): 21-27.
[08]	Sarnak MJ, Katz R, Stehman-Breen CO, Fried LF, Jenny NS, Psaty BM, et al. Cystatin C concentration as a risk factor for heart failure in older adults. Ann Intern Med. 2005; 142 (7): 497-505.
[09]	Liu M, Li XC, Lu L, Cao Y, Sun RR, Chen S, Zhang PY. Cardiovascular disease and its relationship with chronic kidney Disease. Eur Rev Med Pharmacol Sci. 2014 Oct; 18 (19): 291826.
[10]	Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365: 217–223.
[11]	Thankappan KR, Sivasankaran S, Sarma PS, Mini G, Khader SA, Padmanabhan P, et al. Prevalence-correlates-awareness-treatment and control of hypertension in Kumarakom, Kerala: baseline results of a community-based intervention program. Indian Heart J 2006; 58: 28–33.
[12]	Reddy KS. Regional case studies--India. Nestle Nutr Workshop Ser Pediatr Program. 2009; 63: 15-24; discussion 41-6, 259-68.
[13]	Gupta R. Trends in hypertension epidemiology in India. J Hum Hypertens 2004; 18: 73–78.
[14]	Bansal SK, Sexana V, Kandpal SD, Gray WK, Walkar RW, Goel D. The prevalence of hypertension and hypertension risk factors in a rural Indian Community: a prospective door-to-door survey. J Cardiovasc Dis Res. 2012; 3: 117–123
[15]	V Mohan, M Deepa, S Farooq, M Datta, R Deepa. Prevalence, Awareness and Control of Hypertension in Chennai - The Chennai Urban Rural Epidemiology Study (CURES – 52) J Assoc Physicians India. 2007; 55: 326-32.
[16]	P. P. Varma Prevalence of chronic kidney disease in India Whereare we heading? Indian J Nephrol. 2015; 25 (3): 133–135.
[17]	Mehta M, Bhasin SK, Agrawal K, et al. Obesity amongst affluent adolescent girls. Ind J Pediatr. 2007; 74: 619–22.
[18]	Gooneratne IK, Ranaweera AK, Liganarachi NP, Gunawardane N, Lanerolle RD. Epidemiology of chronic kidney disease in a Sri Lankan population. Int J Diabetes Dev Cou. 2008; 28: 60-64.
[19]	Nwankwo EA, Nwankwo B, Mubi B. Prevalence of impaired kidney function in hospitalized hypertensive patients in Maidiguri, Nigeria. Journal of internal Medicine. 2005; 6: 1.